Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET

NCT ID: NCT02425865

Last Updated: 2023-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 202 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-31
• Study Completion Date: 2023-01-31

Brief Summary

PHASE: IV

TYPE OF STUDY: With direct benefit

DESCRIPTIVE: multicenter, open-label, uncontrolled trial

INCLUSION CRITERIA: Adults with moderate to severe ulcerative colitis who failed corticosteroids and immunosupressive therapy, or are intolerant to immunosuppressors. All included patients will be naïve to anti-TNF therapy. Active disease at golimumab treatment initiation defined as a MAYO score ≥6 and with an endoscopic sub score ≥2.

OBJECTIVE: To determine the proportion of patients with Continuous Clinical Response (CCR) and endoscopic remission after one year of golumimab at week 54.

STUDY DESIGN:

Induction Phase :

Week 0: golimumab 200mg- Week 2: golimumab 100 mg- Week 6: golimumab 50 mg

Maintenance Phase I : Week 10-Week 54 Week 10-Week 54 • Patients with primary clinical response*: Standard regimen with golimumab 50 mg Q4W (or 100 mg Q4W if > 80 kg)

• Patients without primary clinical response at week 10 or with flare between week 10-week 54*: Optimization to 100 mg Q4W (or combination therapy with azathioprine if > 80 kg or switch from azathioprine to methotrexate if already on azathioprine at golimumab initiation or patient with known intolerance to thiopurines)
• Early escape at Week 18: Primary non-responders who are still not responding at week 18 to dose optimization at Weeks 10 and 14 will be considered treatment failures and will be followed up (call or visit) at week 54 for safety.

• Clinical response is defined as a decrease from baseline in the Mayo score ≥30% and ≥3 points, accompanied by either a rectal bleeding sub score of 0 or 1 or a decrease from baseline in the rectal bleeding sub score ≥1

Intermittent Phase II : Week 54-Week 108

• Patients with CCR and MH at week 54 and on golimumab 50 mg every 4 weeks: Stop golimumab and continuation of thiopurines or methotrexate if on combination therapy

• Patients with CCR and MH at week 54 and on golimumab 100 mg every 4 weeks: De-escalation to 50 mg every 4 weeks and continuation of thiopurines or methotrexate if on combination therapy

• Restart/Escalate golimumab on flare (defined in section 4 of the protocol) to the phase I dose; 50 mg q4wk or 100mg q4wk (similar to the phase I regimen)

Detailed Description

NUMBER OF PATIENTS: 200 patients

INCLUSION PERIOD: 33 months

STUDY DURATION: 57 months

MAIN EVALUATION Primary endpoints

• Week 10-54: proportion of patients in CCR and with MH (endoscopic Mayo score of 0 or 1) at week 54

Data base lock, data analysis and display (publication) will happen when all included subjects have completed the 108-week visit.

SECONDARY EVALUATION

For all included patients:

• Phase II (week 54-108): proportion of patients in CCR with MH (endoscopic Mayo score of 0 or 1) at week 108, after discontinuation or dose de-escalation (from 100 to 50 mg) of golimumab treatment at year 1 in the subgroup of patients in CCR and with MH (endoscopic Mayo score of 0 or 1) at week 54
• Factors associated with treatment success (see primary endpoint)
• Efficacy of dose optimization in patients who loose response between week 10 and 54
• Clinical remission at week 54 • Clinical remission at week 108 • Partial MAYO score at week 54 and 108 • PRO2 (Partial Mayo minus PGA) at week 54 and 108 • CCR between study inclusion and week 54 and 108 • Steroid-free clinical remission at week 54 and 108 • MH (endoscopic score MAYO 0-1) at week 54 and 108 • Changes in faecal calprotectin levels from baseline to week 54 and 108 • Colectomy between W0 and W54 and 108
• UC-related hospitalizations throughout the trial • Histological remission9 at W54 and 108
• PRO: Fatigue (FACIT), disability (IBD Disability index), QoL (SHS-IBD VAS)
• PK data (golimumab trough levels and antibodies against golimumab)
• Proportion of late responders being in Clinical Response from week 18 to week 54 and with MH at week 54 following treatment intensification in Maintenance Phase

For the subgroup of patients who are primary non-responders to golimumab at week 10, we will assess the efficacy of treatment optimization, including the percentage of patients achieving continuous clinical response and endoscopic remission at one year.

Conditions

ULCERATIVE COLITIS

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

open-label, uncontrolled trial

All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if \> 80 kg

Group Type: OTHER

GOLIMUMAB

Intervention Type: DRUG

Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse

Interventions

GOLIMUMAB

Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age sup 18 years and inf 75 years
• Established diagnosis of UC for at least 3 months (pancolitis, left-sided colitis, proctosigmoiditis and or proctitis are allowed).
• Adults with moderately-to-severely active UC who had an inadequate response to or failed to tolerate steroids AND thiopurines (azathioprine or 6-mercaptopurine) or adults with moderately-to-severely active UC who had no response to an adequate steroid course and starting golimumab.
• Active disease at golimumab treatment initiation defined as a partial MAYO score sup/equal 6 with an endoscopic sub score sup/equal 2.
• Patients concurrently treated with oral corticosteroids will receive a stable dose (prednisone 20 ≤mg/day for at least 2 weeks) before baseline.
• Patient has to be treated with oral 5-ASA at time of inclusion regardless of the dose if no contra-indication. If the patient is not on oral 5-ASA during the screening period, he/she should start mesalamine at 2g per day or asacol at 1.6 g per day, in the absence of contra-indication.
• Patients are allowed stable dose of thiopurines (azathioprine or 6-mercaptopurine stable dose for at least 4 weeks).
• Naïve to anti-TNF therapy, and other biologics, including anti-integrin antibodies and for all biologics known to be effective for UC (approved or investigational).
• Naïve to JAK inhibitors (approved or investigational)
• A contraceptive method during the whole study for childbearing potential female patients.

Exclusion Criteria

• Age under 18 and over 75.
• People unable to give their consent (because of their physical or mental state).
• Absence of written consent.
• Pregnancy or breastfeeding.
• Patients with severe acute colitis or patients at imminent risk for colectomy.
• History of colectomy.
• History of colonic mucosal dysplasia or adenomatous colonic polyps that are not removed.
• Screening stool study positive for enteric pathogens or Clostridium difficile toxin.
• Oral corticosteroids at a dose > 20 mg prednisone or its equivalent per day.
• Any current or previous use of cyclosporine, tacrolimus, anti-TNF therapy, and other biologics, including anti-integrin antibodies (approved or investigational), JAK inhibitors (approved or investigational), or any current or previous use of an investigational agent within 5 half-lives of that agent before the first study agent injection.
• Contraindication to anti-TNF therapy according to drug labelling:

• Active infection.
• Non-treated latent tuberculosis.
• Heart failure (NYHA: Grade III and IV).
• Malignancy during the previous 5 years.
• Demyelinating neurological disease.
• Should be vaccinated with attenuated live vaccines

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Laurent Peyrin Biroulet, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Lucine Vuitton, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Edouard Louis, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire de Liege

Locations

CHU LIEGE - Sart Tilman

Liège, , Belgium

CHU Dinant Godinne UCL Namur

Namur, , Belgium

CHU Amiens

Amiens, , France

Chu Besancon

Besançon, , France

Caen Unversity Hospital

Caen, , France

CHU Clermont Ferrand

Clermont-Ferrand, , France

APHP- Hopital BEAUJON

Clichy, , France

CHU de Colmar- Hopital Trousseau Medecine A

Colmar, , France

CHRU Lille

Lille, , France

CHU de Montpellier- Hopital saint Eloi

Montpellier, , France

CHU NANTES - Hôpital Hôtel Dieu

Nantes, , France

CHU de NICE- Hopital Archet 2

Nice, , France

CHU de Nimes- Hopital Carémeau

Nîmes, , France

APHP- Hopital BICHAT

Paris, , France

CHU Bordeaux- Hopital Haut Levèque

Pessac, , France

CHU LYON- Hopital Lyon Sud

Pierre-Bénite, , France

Chu Reims

Reims, , France

CHU RENNES - Hopital Pontchaillou

Rennes, , France

CHU de Saint Etienne- Hopital Nord

Saint-Priest-en-Jarez, , France

Chu Strasbourg

Strasbourg, , France

CHU de TOULOUSE

Toulouse, , France

CHU de Tours - Hopital Trousseau

Tours, , France

CHU NANCY - Hopital Brabois

Vandœuvre-lès-Nancy, , France

Countries

Belgium; France

Other Identifiers

GETAID 2015-05

Identifier Type: -

Identifier Source: org_study_id